Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGT NASDAQ:IMVT NASDAQ:KALV NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$32.92+5.3%$35.50$4.75▼$43.73$5.34B0.371.50 million shs2.04 million shsIMVTImmunovant$35.56+35.3%$26.48$13.79▼$36.29$5.35B0.71.41 million shs19.56 million shsKALVKalVista Pharmaceuticals$26.81+0.1%$21.02$9.83▼$26.85$1.43B-0.127.21 million shs5.54 million shsXENEXenon Pharmaceuticals$54.68+1.2%$56.38$28.19▼$63.95$5.22B0.65929,176 shs1.05 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences+5.34%-4.00%-11.03%-14.14%+519.96%IMVTImmunovant+35.26%+21.57%+24.64%+34.90%+137.07%KALVKalVista Pharmaceuticals+0.20%+0.04%+28.46%+68.72%+119.04%XENEXenon Pharmaceuticals+1.17%-2.15%-4.22%+26.93%+73.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$32.92+5.3%$35.50$4.75▼$43.73$5.34B0.371.50 million shs2.04 million shsIMVTImmunovant$35.56+35.3%$26.48$13.79▼$36.29$5.35B0.71.41 million shs19.56 million shsKALVKalVista Pharmaceuticals$26.81+0.1%$21.02$9.83▼$26.85$1.43B-0.127.21 million shs5.54 million shsXENEXenon Pharmaceuticals$54.68+1.2%$56.38$28.19▼$63.95$5.22B0.65929,176 shs1.05 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences+5.34%-4.00%-11.03%-14.14%+519.96%IMVTImmunovant+35.26%+21.57%+24.64%+34.90%+137.07%KALVKalVista Pharmaceuticals+0.20%+0.04%+28.46%+68.72%+119.04%XENEXenon Pharmaceuticals+1.17%-2.15%-4.22%+26.93%+73.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.86Moderate Buy$43.7332.83% UpsideIMVTImmunovant 2.45Hold$32.44-8.76% DownsideKALVKalVista Pharmaceuticals 2.22Hold$30.6014.14% UpsideXENEXenon Pharmaceuticals 3.00Buy$77.0740.94% UpsideCurrent Analyst Ratings BreakdownLatest KALV, IMVT, COGT, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026XENEXenon Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$77.00 ➝ $80.005/10/2026XENEXenon Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$69.005/8/2026XENEXenon Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $82.005/8/2026XENEXenon Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$80.00 ➝ $78.005/6/2026COGTCogent Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.005/1/2026KALVKalVista Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$37.00 ➝ $27.004/30/2026KALVKalVista Pharmaceuticals JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2026KALVKalVista Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/29/2026KALVKalVista Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/29/2026KALVKalVista Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/21/2026KALVKalVista Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$3.18 per shareN/AIMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AKALVKalVista Pharmaceuticals$49.08M29.08N/AN/A($0.37) per share-72.46XENEXenon Pharmaceuticals$7.50M704.79N/AN/A$13.84 per share3.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)IMVTImmunovant-$413.84M-$2.69N/AN/AN/AN/A-63.17%-58.01%N/AKALVKalVista Pharmaceuticals-$109.52M-$3.46N/A45.44N/AN/A-341.44%-111.94%N/AXENEXenon Pharmaceuticals-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%N/ALatest KALV, IMVT, COGT, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/15/2026Q1 2026KALVKalVista Pharmaceuticals-$0.3763-$0.43-$0.0538-$0.43$39.03 million$39.17 million5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/A5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A2/26/2026Q4 2025XENEXenon Pharmaceuticals-$1.20-$1.31-$0.11-$1.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent Biosciences0.4115.1415.14IMVTImmunovantN/A15.7415.74KALVKalVista Pharmaceuticals8.185.175.10XENEXenon PharmaceuticalsN/A27.7927.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/AIMVTImmunovant47.08%KALVKalVista PharmaceuticalsN/AXENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences7.29%IMVTImmunovant1.80%KALVKalVista Pharmaceuticals4.30%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80170.87 million158.41 millionOptionableIMVTImmunovant120203.53 million199.87 millionOptionableKALVKalVista Pharmaceuticals10053.24 million50.95 millionOptionableXENEXenon Pharmaceuticals21096.67 million92.73 millionOptionableKALV, IMVT, COGT, and XENE HeadlinesRecent News About These CompaniesWhat to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA FilingMay 19 at 7:29 PM | finance.yahoo.comDNB Asset Management AS Acquires 23,750 Shares of Xenon Pharmaceuticals Inc. $XENEMay 18 at 3:44 AM | marketbeat.comXenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 14, 2026 | seekingalpha.comStock Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)May 14, 2026 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $80.00 at JPMorgan Chase & Co.May 12, 2026 | marketbeat.comEquities Analysts Set Expectations for XENE Q2 EarningsMay 12, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Sells 35,973 Shares of Xenon Pharmaceuticals Inc. $XENEMay 12, 2026 | marketbeat.comA Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash RunwayMay 11, 2026 | finance.yahoo.comDid Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?May 11, 2026 | finance.yahoo.comNan Fung Trinity HK Ltd. Has $10.17 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENEMay 10, 2026 | marketbeat.comXenon Pharmaceuticals Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comXenon Highlights Positive Phase 3 Azetukalner Seizure DataMay 8, 2026 | theglobeandmail.comXenon Q1 earnings match estimates, pipeline development in focusMay 8, 2026 | msn.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysMay 8, 2026 | marketbeat.comNeedham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $78.00May 8, 2026 | marketbeat.comXenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comXenon Pharmaceuticals: Q1 Earnings SnapshotMay 7, 2026 | finance.yahoo.comXenon (XENE) Q1 2026 Earnings TranscriptMay 7, 2026 | finance.yahoo.comXenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comXenon Reports Q1 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comXenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026May 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALV, IMVT, COGT, and XENE Company DescriptionsCogent Biosciences NASDAQ:COGT$32.92 +1.67 (+5.34%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$33.05 +0.13 (+0.39%) As of 05/20/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Immunovant NASDAQ:IMVT$35.56 +9.27 (+35.26%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$35.39 -0.17 (-0.48%) As of 05/20/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.KalVista Pharmaceuticals NASDAQ:KALV$26.81 +0.04 (+0.15%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$26.80 -0.01 (-0.06%) As of 05/20/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Xenon Pharmaceuticals NASDAQ:XENE$54.68 +0.63 (+1.17%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$54.67 -0.01 (-0.02%) As of 05/20/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
